Body

Best use of drug-eluting stents

Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction. The use of drug-eluting stents necessitates extended treatment with dual antiplatelet therapy (aspirin plus thienopyridine) which may cause bleeding complications and interferes with or even precludes surgery in case this is needed.

In addition, from a socioeconomic standpoint, the increased cost associated with drug-eluting stents is a major issue.

Should we use echocardiography to screen young athletes?

Sudden and unexpected deaths in young competitive athletes are uncommon but highly visible events, which raise concern and ethical issues in both the lay public and medical community. Which is the best strategy to timely identify individuals with cardiac disease responsible for sudden death (primarily, HCM) is largely debated. Namely, the extent to which sophisticated testing, such as echocardiography, is needed is still undefined.

DES in diabetic patients

The issue of using or not using DES in patients with diabetes will be debated between Professor Wijns, who discourages DES and Professor Silber, who feels that they should be used.

Positive exercise testing in athletes: What does that mean?

Sudden cardiac death (SCD) during sports activity is an uncommon, but catastrophic event. Different efforts to reduce the risk of SCD related to sports have been undertaken. What is the role of the exercise test in this context? What does a positive exercise test mean?

Who needs surgery?

Genetic testing?

Frequently, autopsy becomes the principal diagnostic tool when macro and microscopic analyses provide a conclusive diagnosis in cardiomyopathies. However, on average one third of autopsies do not identify a pathologically defined cause of death and these deaths are classified as "natural" or arrhythmogenic. In the athlete, the most common causes of sudden cardiac death are of inherited origin. This represents a tremendous burden to families, community and health care.

DES: New elements in the debate

Results announced at the 2006 ESC meeting in Barcelona questioned the long-term safety of drug eluting stents (DES) and sparked intense discussion.

Sports-related sudden cardiac death is reduced by pre-participation cardiovascular screening

Data on investigational Factor Xa compound presented at European heart meeting

MUNICH – Data from a Phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy, according to researchers at the Duke Clinical Research Institute.

While the results of the study did not show a statistically significant difference in ischemic events among any of the four doses of apixaban evaluated, trends emerged that support further study, the scientists said.

September Ophthalmology research highlights

SAN FRANCISCO, CA--- Doctors and medical centers across the United States are debating the use of electronic health records (EHR). This month’s Ophthalmology, the journal of the American Academy of Ophthalmology, provides a look at Eye M.D.s’ actions and opinions on the issue. Also highlighted this month are two research studies that will help doctors identify patients who are most vulnerable to advanced age-related macular degeneration (AMD), the leading cause of severe vision loss in the United States and most Western countries.